Alaa Atamna
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Alaa Atamna has a total of 26 co-authors. Here are the top co-authors by number of shared publications:
Adi Bachar
Department of Vascular Surgery, Rabin Medical Center, Beilinson Hospital, Petach Tikvah, Israel
1 shared publicationAlon Burg
Department of Orthopedics, Rabin Medical Center, Beilinson Hospital, Petach Tikvah, Israel; Sackler Faculty of Medicine, Tel Aviv University, Tel-Aviv, Israel
1 shared publicationAvishay Elis
Internal Medicine C, Rabin Medical Center, Beilinson Hospital, Petach Tikvah, Israel; Sackler Faculty of Medicine, Tel Aviv University, Tel-Aviv, Israel
1 shared publication- Bibiana Chazan
Department of Infectious Diseases, Emek Medical Center, Afula, Israel
1 shared publication - Dafna Yahav
Infectious Diseases Unit, Sheba Medical Center, Ramat Gan, Israel
1 shared publication - Eugene Katchman
Tel Aviv Sourasky Medical Center, Tel Aviv 6997801, Israel
1 shared publication
Latest Publications
- Open Access
- 9 July 2022
- Published by MDPI AG in Journal of Fungi
- Vol. 8 (7) , 721
Invasive Fungal Diseases in Hospitalized Patients with COVID-19 in Israel: A Multicenter Cohort Study
Highly variable estimates of COVID-19-associated fungal diseases (IFDs) have been reported. We aimed to determine the incidence of clinically important fungal diseases in hospitalized COVID-19 patients during the first year of the pandemic. We performed a multicenter survey of IFDs among patients hospitalized with COVID-19 in 13 hospitals in Israel between February 2020 and May 2021. COVID-19-associated pulmonary mold disease (PMD) and invasive candidiasis (IC) were defined using ECMM/ISHAM and EORTC/MSG criteria, respectively. Overall rates of IC and PMD among patients with critical COVID-19 were 10.86 and 10.20 per 1000 admissions, respectively, with significant variability among medical centers. PMD rates were significantly lower in centers where galactomannan was a send-out test versus centers with on-site testing (p = 0.035). The 30-day mortality rate was 67.5% for IC and 57.5% for PMD. Treatment with an echinocandin for IC or an extended-spectrum azole for PMD was associated with significantly lower mortality rates (adjusted hazard ratio [95% confidence interval], 0.26 [0.07–0.91] and 0.23 [0.093–0.57], respectively). In this multicenter national survey, variable rates of PMD were associated with on-site galactomannan testing, suggesting under-detection in sites lacking this capacity. COVID-19-related IFDs were associated with high mortality rates, which were reduced with appropriate antifungal therapy.
- 9 July 2022
- Published by MDPI AG in Journal of Fungi
- Vol. 8 (7) , 721
Open AccessInvasive Fungal Diseases in Hospitalized Patients with COVID-19 in Israel: A Multicenter Cohort Study
Highly variable estimates of COVID-19-associated fungal diseases (IFDs) have been reported. We aimed to determine the incidence of clinically important fungal diseases in hospitalized COVID-19 patients during the first year of the pandemic. We performed a multicenter survey of IFDs among patients hospitalized with COVID-19 in 13 hospitals in Israel between February 2020 and May 2021. COVID-19-associated pulmonary mold disease (PMD) and invasive candidiasis (IC) were defined using ECMM/ISHAM and EORTC/MSG criteria, respectively. Overall rates of IC and PMD among patients with critical COVID-19 were 10.86 and 10.20 per 1000 admissions, respectively, with significant variability among medical centers. PMD rates were significantly lower in centers where galactomannan was a send-out test versus centers with on-site testing (p = 0.035). The 30-day mortality rate was 67.5% for IC and 57.5% for PMD. Treatment with an echinocandin for IC or an extended-spectrum azole for PMD was associated with significantly lower mortality rates (adjusted hazard ratio [95% confidence interval], 0.26 [0.07–0.91] and 0.23 [0.093–0.57], respectively). In this multicenter national survey, variable rates of PMD were associated with on-site galactomannan testing, suggesting under-detection in sites lacking this capacity. COVID-19-related IFDs were associated with high mortality rates, which were reduced with appropriate antifungal therapy.
- 1 December 2021
- Published by Elsevier in European Journal of Internal Medicine
- Vol. 94, 64-68
Multidisciplinary team led by internists improves diabetic foot ulceration outcomes a before-after retrospective study
- 1 December 2021
- Published by Elsevier in European Journal of Internal Medicine
- Vol. 94, 64-68
Multidisciplinary team led by internists improves diabetic foot ulceration outcomes a before-after retrospective study